Organophosphate And Carbamate Poisoning - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 41 pages report, published by Global Markets Direct

Keywords : Organophosphate And Carbamate Poisoning Therapeutic Products under Development, Key Players in Organophosphate And Carbamate Poisoning Therapeutics, Organophosphate And Carbamate Poisoning Pipeline Overview, Organophosphate And Carbamate Poisoning Pipeline, Organophosphate And Carbamate Poisoning Pipeline Assessment

Report ThumbnailSeptember-2013
Organophosphate And Carbamate Poisoning - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Organophosphate And Carbamate Poisoning - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Organophosphate And Carbamate Poisoning, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Organophosphate And Carbamate Poisoning. Organophosphate And Carbamate Poisoning - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Organophosphate And Carbamate Poisoning.
- A review of the Organophosphate And Carbamate Poisoning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Organophosphate And Carbamate Poisoning pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Organophosphate And Carbamate Poisoning.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Organophosphate And Carbamate Poisoning pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Organophosphate And Carbamate Poisoning, H2 2013 7
  • Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Organophosphate And Carbamate Poisoning, H2 2013 7
  • Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • Baxter International Inc., H2 2013 16
  • PharmAthene, Inc., H2 2013 17
  • Protalix BioTherapeutics, Inc., H2 2013 18
  • MicroDose Therapeutx, Inc., H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates 32
  • Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products 34
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Organophosphate And Carbamate Poisoning Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Organophosphate And Carbamate Poisoning 7
  • Organophosphate And Carbamate Poisoning Therapeutics under Development by Companies 9
  • Organophosphate And Carbamate Poisoning Therapeutics under Investigation by Universities/Institutes 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Organophosphate And Carbamate Poisoning Therapeutics - Products under Development by Companies 14
  • Organophosphate And Carbamate Poisoning Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Organophosphate And Carbamate Poisoning Therapeutics Development 16
  • Baxter International Inc. 16
  • PharmAthene, Inc. 17
  • Protalix BioTherapeutics, Inc. 18
  • MicroDose Therapeutx, Inc. 19
  • Organophosphate And Carbamate Poisoning - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • PRX-105 - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • MDT-011 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • atropine sulfate - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • Plasma Derived Butyrylcholinesterase - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • Organophosphate Antidote CR - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Second Generation Protexia - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates 32
  • Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products 34
  • Organophosphate And Carbamate Poisoning - Product Development Milestones 35
  • Featured News & Press Releases 35
  • Apr 17, 2013: PharmAthene's Recombinant Butyrylcholinesterase Successfully Targets Nerve Agents In In-Vitro Study 35
  • Jun 07, 2011: MicroDose Therapeutx Announces Successful Completion Of Phase I Pilot Study Of Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning 35
  • Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day 36
  • Jun 08, 2010: Protalix Completes Phase I Clinical Trial For PRX-105 37
  • Sep 23, 2009: MicroDose Therapeutx Announces Initiation Of Phase I Study With Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning 37
  • May 15, 2007: King Pharmaceuticals AtroPen Receives DHS Safety Act Designation 38
  • Jun 20, 2003: King Pharmaceuticals Atropen Approved By FDA 39
  • Appendix 40
  • Methodology 40
  • Coverage 40
  • Secondary Research 40
  • Primary Research 40
  • Expert Panel Validation 40
  • Contact Us 41
  • Disclaimer 41

Please select a license type

Share

Related Products

Global Markets DirectOrganophosphate And Carbamate Poisoning - Pipeline Review, H2 2013Product ThumbnailOrganophosphate And Carbamate Poisoning - Pipeline Review, H2 2013, Industry ReportProduct #: 113358
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved